Eye diseases can range from minor irritations to serious conditions that threaten vision if left untreated. Thankfully, advances in ophthalmic drug development are providing new treatment options for patients. Here is an overview of some key drugs and areas of progress in this field.
Anti-inflammatories
Inflammation is a major component of many eye conditions such as uveitis, conjunctivitis, keratitis and blepharitis. Newer anti-inflammatory drugs are improving outcomes for these diseases.
Corticosteroids
Corticosteroids have long been the mainstay for treating ocular inflammation. New drug delivery methods such as dexamethasone intravitreal implants provide sustained drug release over months, reducing the need for frequent eye injections or drops. This improves compliance and lowers risks of adverse effects from high corticosteroid levels that can occur with traditional eye drops.
Biologics
Biologics targeting specific inflammatory pathways are revolutionizing treatment for uveitis and other conditions. TNF inhibitors such as infliximab and adalimumab have shown great promise for uveitis. Novel biologics targeting IL-17 and IL-23 pathways are in development and clinical trials, showing potential for difficult-to-treat cases. These biologic therapies provide newer options with less systemic side effects than traditional corticosteroids or immunosuppressants.
Glaucoma
Lowering elevated intraocular pressure (IOP) is key to preventing vision loss from glaucoma. While topical eye drops remain first-line, newer drug classes and delivery methods are being studied.
Rho kinase (ROCK) inhibitors
ROCK inhibitors work via a novel mechanism to reduce IOP by increasing aqueous humor outflow through the trabecular meshwork. Ripasudil is now approved in Japan and is undergoing clinical trials elsewhere. It shows potential as an adjunct or alternative to prostaglandin analogs.
Gene therapy
Gene therapy aims to treat glaucoma at its root cause by transferring genes into cells to increase production of certain proteins involved in aqueous humor drainage. Several gene therapy candidates are in clinical trials, with encouraging early results in lowering IOP compared to medication alone. This could transform glaucoma management if results hold up in larger trials.
Anti-infectives
Bacterial, viral and fungal eye infections are common sight-threatening conditions, especially in developing areas or immunocompromised patients. New antifungal, antiviral and antibiotic drugs and drug combinations are needed to combat resistance.
Mast cell stabilizers
Allergic conjunctivitis is an Ophthalmic Drugs umbrella term for various forms of seasonal and perennial allergies affecting the eyes. While first-generation antihistamines are commonly used, second-generation mast cell stabilizers directly interfere with mast cell degranulation to provide more targeted relief of itching and redness. New dual-acting mast cell stabilizer/antihistamine formulations show promise.
Retinal diseases
Diabetic retinopathy, wet age-related macular degeneration, retinal vein occlusions - these complex retinopathies demand innovative new treatments.
Anti-VEGF drugs
Ranibizumab, aflibercept, and bevacizumab are the backbone of treating wet AMD and other retinal vascular diseases by inhibiting VEGF to block abnormal blood vessel growth. Sustained-release implants and nanoparticle drug carriers are under study to reduce injection frequency compared to current monthly or bi-monthly doses.
Neuroprotection
As retinal ganglion cell and nerve fiber layer loss underlie glaucoma vision loss, drugs protecting these cells offer hope to stall or even reverse damage. NGF mimics and drugs suppressing apoptosis signaling pathways are two areas of active research.
Advances across anti-inflammatory, anti-infective, neuroprotective and anti-angiogenic classes hold promise for many blinding eye diseases. Sustained and targeted delivery, novel mechanisms of action, and combination therapies will likely define the future of ophthalmic pharmacology. With continued research, we may see transformational new treatments to revolutionize patient care and vision preservation.
Get more insights on- Ophthalmic Drugs
Check more trending articles related to this topic: Singapore Meetings, Incentives, Conferences and Exhibitions (MICE) Market
Transparency Market Research (TMR) has published a new report titled, ‘Ophthalmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.
According to the report, the global Ophthalmic Drugs Market was valued at US$ 26,018.3 Mn in 2018 and is projected to expand at a CAGR of 4.1% from 2019 to 2027.Read Report Overview - https://www.transparencymarketresearch.com/ophthalmic-drugs-market.htmlOverviewOphthalmic Drugs are the anti-infectives drugs that contained in a product formulated especially to be instilled or applied in the eye or eyes.
Ophthalmic anti-infectives include eye drops, gels or ointments.
Highly structured health care industry and introduction of the Affordable Care Act in the U.S. are expected to drive the market in North America.Asia Pacific is likely to be a highly lucrative market for retinal disorders and it is expected to expand at a high CAGR during the forecast periodRequest Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1769Increasing incidence rates of eye related disorders to Drive MarketThere is an alarming rise in incidence of eye related diseases, especially in the developed countries, which is anticipated to drive the growth of the ophthalmic drugs market during 2017-2025According to the Prevent Blindness report, the number of people in the U.S., suffering from cataract is expected to increase from4 Mnin 2010, to 30.5 Mn by 2020, and people suffering from diabetic retinopathy in U.S. are projected to increase from 7.7 Mn in 2010 to 9.2 Mn in 2020The patients for open angle glaucoma and AMD in U.S., were 7 Mn and 2.1 Mn, respectively, which are projected to increase to3.3 Mn and 2.5 Mn, respectively, till 2020The increasing patient pool in developing countries as well as developed regions is estimated to propel healthcare spending for eye treatments in each region and drive the growth of the ophthalmic drugs market.Advanced retinal treatment approvals for unmet needs in eye disorders to drive the marketEye diseases such as chronic or recurrent uveitis, optic nerve, neurodegeneration retinitis pigmentosa, retinoblastoma, etc., lack an effective treatment option, and thus are categorized as unmet medical needs within the ophthalmologic diseases spaceSeveral new entrants are dedicated to provide specialized treatment methods for eye diseases:On May 18 2017,Spark Therapeutics, Inc. submitted the first and only Biological License Application to the U.S. FDA for the treatment of Leber’s congenital amaurosis by gene therapyOn March 25 2015, Regeneron Pharmaceuticals Inc., announced the approval of Eylea, the first VEGF inhibitor approved for dosing on a less than monthly basis for the treatment of diabetic macular edemaSevere inflammatory eye diseases, such as uveitis, lacked a solid treatment option earlier to the FDA approval of Humira for the indication of non-infectious intermediate, posterior, and panuveitis in adult patientsIn June 2016,the U.S. FDA approved the first and only biologic approved drug, Humira, for the treatment of uveitisSuch approvals for advanced treatment options for the treatment of unmet medical needs in the field of eye disorders are projected to boost the expansion of the global ophthalmic drugs marketRequest COVID Analysis on Ophthalmic Drugs Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=1769Dry Eye Segment to Dominate MarketBased on Disease Indication, the global Ophthalmic Drugs Market has been divided into Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, Allergy, Uveitis, Others.
The Retinal Disorders segment has been bifurcated into Wet AMD, Dry AMD, Diabetic Retinopathy, Others.
The market is witnessing significant transformations due to changing Medicare policies in the U.S., pricing of branded specialty drugs, and the rising patient pool.The increasing patient number along with rising health initiatives for treatment awareness are projected to drive the demand for ophthalmic drugs in this region.The Ophthalmic Drugs Market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027.
The global ophthalmic drugs market is witnessing rapid increase over the past few years, mainly due to the rising prevalence of eye-related diseases & disorders.
Recent advances in medical technologies such as AMPPLIFY technology that demonstrates higher delivery of a drug into ocular tissues are escalating the market on the global platform.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/5753An eminent research firm Market Research Future (MRFR) states that the global ophthalmic drugs market size had reached USD 29.46 BN in 2018, and the market valuation would further appreciate at around 5.1% CAGR during the forecast period (2019 to 2025).
Substantial R investments into drug discoveries are another major tailwind pushing the market growth excellently, bringing about novel medicines to treat various ophthalmic diseases.
Furthermore, recent development & commercialization of several drugs boost the market growth.Global Ophthalmic Drugs Market – SegmentsThe report has been segmented into five major dynamics.By Dosage Form : Eye Drops, Ointments, Solutions, Gels, Capsules & Tablets, and others.By Product Type : Prescription Drug and OTC Drug.By Drug Class : Antibiotics, Anti-Inflammatory, Anti-Glaucoma, and others.By Indication : Glaucoma, Retinal Disorder, Dry Eye, Eye Allergy, and others.By Regions : Europe, Americas, Asia Pacific, Middle East & Africa, and Rest-of-the-World.Global Ophthalmic Drugs Market – Regional AnalysisNorth America leads the global ophthalmic drugs heading with the presence of the many major players and a large patient population suffering from eye diseases.
Moreover, the availability of well-developed technology and high healthcare expenditures, alongside the rising prevalence of eye diseases in the region, drives the market growth significantly.Also, the growing demand for eye care led by the increasing numbers of patients suffering from chronic diseases such as diabetes, neurovascular, and different eye disorders impacts market growth positively.
Additionally, augmenting demand for the minimally invasive & technologically advanced treatments, alongside the governmental support for R funding are expected to drive the regional market growth, commutatively.Europe's ophthalmic drugs market is proliferating rapidly.
The global ophthalmic drugs market size is expected to reach USD 45.8 billion by 2027, registering a CAGR of 5.0%, according to a new report published by Radiant Insights, Inc. Advancements in drug delivery systems are anticipated to drive the overall growth.
In December 2017, Spark Therapeutics received Food and Drug Administration (FDA) approval for the first gene therapy drug in the ophthalmic market-Luxturna (voretigene neparvovec-rzyl).
Download Free Sample Report @ https://www.radiantinsights.com/research/ophthalmic--drugs-market/request-sample Increasing number of strategic mergers, acquisitions, and collaborations make the market for ophthalmic drugs a highly competitive space.
Premium services and high-volume ancillary value-added businesses deliver supplementary benefits to customers and attract investments in the market.
For instance, in July 2019, Bausch & Lomb Incorporated announced launch of Ocuvite, an eye vitamin supplement to strengthen the macula for the U.S. market.
Due to increasing awareness of ophthalmic disorders and surge in the demand of these products, ophthalmic drug manufacturers are expanding their presence in the emerging economies by supporting various awareness campaigns in different regions.
The global ophthalmic drugs market size is expected to reach USD 45.8 billion by 2027, registering a CAGR of 5.0%, according to a new report published by Radiant Insights, Inc. Advancements in drug delivery systems are anticipated to drive the overall growth.
In December 2017, Spark Therapeutics received Food and Drug Administration (FDA) approval for the first gene therapy drug in the ophthalmic market-Luxturna (voretigene neparvovec-rzyl).
Download Free Sample Report @ https://www.radiantinsights.com/research/ophthalmic--drugs-market/request-sample Increasing number of strategic mergers, acquisitions, and collaborations make the market for ophthalmic drugs a highly competitive space.
Premium services and high-volume ancillary value-added businesses deliver supplementary benefits to customers and attract investments in the market.
For instance, in July 2019, Bausch & Lomb Incorporated announced launch of Ocuvite, an eye vitamin supplement to strengthen the macula for the U.S. market.
Due to increasing awareness of ophthalmic disorders and surge in the demand of these products, ophthalmic drug manufacturers are expanding their presence in the emerging economies by supporting various awareness campaigns in different regions.
